19815 Bay Branch Rd
Andalusia, Alabama 36420
(334) 222-2523
HELPLINE: 1-877-530-0002



Facebook    

 

SCAMHC is an approved Mental Health site for the National Health Service Corps Loan Repayment program.  Find out the program details and see if you qualify by visiting: http://nhsc.hrsa.gov/

SCAMHC is an Equal Opportunity Provider and Employer and maintains a Drug-Free Workplace.

SCAMHC serves all individuals regardless of inability to pay. Discounts for essential services are offered based on family size and income. For more information, contact (334) 222-2523 or our 24/7 Helpline at 1-877-530-0002.

 

 


powered by centersite dot net
Child & Adolescent Development: Overview
Resources
Basic InformationMore InformationLatest News
Pfizer Says Lower Dose of Its COVID Vaccine Protects Younger ChildrenWhite House Announces COVID Vaccination Plan for Young KidsMany Parents Worry That Kids Fell Behind in Schooling During PandemicNew Device Might Spot 'Lazy Eye' in Kids EarlierA High-Tech Pointer to Pollutants That Trigger Asthma in KidsU.S. Pediatricians, Psychiatrists Declare 'Emergency' in Child Mental HealthState Spending on Poverty Really Pays Off for Kids: StudyNature Helped Many Kids Cope During Lockdown: StudyTwo-Thirds of Parents of Kids Ages 5-11 Plan to Get Them Vaccinated Against COVID: PollKids Can Carry High, Infectious Levels of COVID CoronavirusBystanders Can Make the Difference for a Drowning ChildAs COVID Cases Drop, Fauci Tells Families to Enjoy HalloweenGolf Cart Injuries Keep Rising Among U.S. KidsStudy Confirms Rise in Child Abuse During COVID PandemicSocial Distancing Kept Kids From Getting Flu, RSVPfizer Seeks FDA Emergency Approval for COVID Vaccine in Younger KidsCould an App Help Kids With Severe Ear Condition Avoid Surgery?Kids With Food Allergies Are Often Targets for BulliesAbuse in Childhood May Shorten Adult Lives: StudyAs Kids Turned to Screens During Pandemic, Their Mental Health SufferedRacial Disparities Persist With Childhood Cancers1 in 4 Parents Say Their Kids Have Been Quarantined Since School StartedA Simple Way to Boost Kids' Reading Skills?Sibling Bullying Carries Long-Term Mental Health CostsActive Learning Best for Students: StudyBlack Parents Most Hesitant About COVID Vaccines for Kids: PollPfizer Sends First Data to FDA on COVID Vaccines for Younger KidsWeight Loss Surgery a Good Option for Severely Obese Kids: StudyTough Choices: Chemo That Can Save Kids With Cancer Can Also Damage HearingOver Half of American Children Have Detectable Lead Levels in Their BloodMask Mandates in Schools Curb Infections, CDC Studies ShowPfizer to Ask FDA Soon for Approval of Its COVID Vaccine for Younger ChildrenKeep Your Kids Safe From COVID While Playing SportsNew Tricks to Turn Your Fussy Eater AroundWeight Loss in Childhood May Protect Boys Against Future InfertilityChildhood Trauma Linked With Higher Odds for Adult Neurological IllsParents of Hospitalized Kids Need More Info on Costs: StudyWhich Kids Are at Highest Risk From COVID?Watch Their Backs -- Don't Overload Those SchoolbagsDoctors Often Miss Signs of Type 1 Diabetes in KidsNeighborhood Gun Violence Means Worse Mental Health for KidsLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyChild Obesity Rose Sharply During PandemicCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciChild Cancers Are Rare, But Here Are Signs to Look ForGetting Kids Eyeglasses Boosts School Grades: StudyKids' Temporary Tattoos Can Harm Skin FunctionEczema Can Take Toll on Child's Mental HealthCOVID Cases Rise Sharply Among Kids as School Year Starts
Questions and AnswersVideosLinksBook Reviews
Related Topics

ADHD: Attention Deficit Hyperactivity Disorder
Childhood Mental Disorders and Illnesses
Parenting

Lower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company Says

HealthDay News
by By Robin Foster HealthDay Reporter
Updated: Sep 20th 2021

new article illustration

MONDAY, Sept. 20, 2021 (HealthDay News) -- A smaller dose of Pfizer's coronavirus vaccine safely triggers a strong immune response in children as young as 5, the company announced Monday morning.

"Over the past nine months, hundreds of millions of people ages 12 and older from around the world have received our COVID-19 vaccine. We are eager to extend the protection afforded by the vaccine to this younger population, subject to regulatory authorization, especially as we track the spread of the Delta variant and the substantial threat it poses to children," Pfizer Chairman and CEO Albert Bourla said in a statement.

"Since July, pediatric cases of COVID-19 have risen by about 240 percent in the U.S. -- underscoring the public health need for vaccination," Bourla added. "These trial results provide a strong foundation for seeking authorization of our vaccine for children 5 to 11 years old, and we plan to submit them to the FDA and other regulators with urgency."

The finding, which will likely come as welcome news to many parents and pediatricians, is a crucial step toward Pfizer's two-shot regimen becoming available for younger school-aged children as early as Halloween, the Washington Post reported. The pediatric dose used in the trial was one-third the strength of the adult shots.

With coronavirus cases soaring among children as the school year gets underway, pediatricians have been flooded with requests to bend the rules and give children a shot now, the Post reported. The new data seems likely to intensify that pressure, even though Pfizer's existing vaccine is triple the dose tested in the trial.

"No one should really be freelancing — they should wait for the appropriate approval and recommendations to decide how best to manage their own children's circumstances," William Gruber, Pfizer's senior vice president of vaccine clinical research and development, told the Post, explaining that younger children tend to have more "exuberant" immune responses to vaccines than older people do.

"Nature has equipped us, particularly when we are young, to respond very well to an assortment of things we will encounter in nature — and we will use vaccines to accelerate that process and really improve on nature," Gruber added.

Among 12- to 17-year-olds eligible for the Pfizer shot since May, only about half have received at least one dose, according to the American Academy of Pediatrics. More than 5 million cases of COVID-19, the illness caused by the coronavirus, have been reported among children and teens, causing 20,000 hospitalizations and 460 deaths since the start of the pandemic. As children have returned to classrooms, many families and schools have been navigating disruptive quarantines and divisive masking policies.

In July, the FDA asked Pfizer and Moderna to increase the size of their pediatric trials to ensure the safety data was robust, the Post reported. There were nearly 2,300 children between the ages of 5 and 11 in Pfizer's trial, two-thirds of whom received the vaccine. The rest received saline shots.

The trial showed that children who received the vaccine had immune responses similar to those seen in teens and young adults, according to Pfizer. Two shots of a 10-microgram dose, spaced three weeks apart, were well-tolerated.

Gruber said there appeared to be less fever and fewer chills among younger children than in a comparison group of 16- to 25-year-olds, bolstering the company's confidence that it had found the right dose.

Pfizer is seeking emergency use authorization for the pediatric vaccine dose as it continues to gather data to support full approval in children. Data on children younger than 5 is expected by the end of the year, the Post reported. Moderna is also conducting a trial in children as young as six months.

More information

Visit the U.S. Centers for Disease Control and Prevention for more on COVID vaccines.


SOURCE: Washington Post; Pfizer Inc., news release, Sept. 20, 2021